格隆汇1月23日丨太极集团(600129.SH)在投资者互动平台表示，目前，公司暂未建立财务共享中心，未 来公司将结合实际情况开展筹建。公司加快推动运营管理数字化转型升级，开展内部业务平台数字化建 设，构建敏捷高效的流程管理体系，已建立财务管控平台，基于ERP管理系统，构建业财税一体化管理 平台，打通业务、财务、税务管理系统壁垒，形成互联互通、相互制约的管理闭环。 ...

Core Viewpoint - The company, Chongqing Taiji Industry (Group) Co., Ltd., announced a capital increase of 46.7 million yuan for its wholly-owned subsidiary, Yuncheng Taiji Smart Traditional Chinese Medicine Co., Ltd., to enhance its financial stability and market competitiveness [1] Group 1: Capital Increase Details - The registered capital of Yuncheng Smart Traditional Chinese Medicine will increase from 300,000 yuan to 47 million yuan following the capital injection [1] - The capital increase aims to supplement the subsidiary's working capital, optimize its asset-liability structure, and enhance its capital strength and risk resistance [1] Group 2: Strategic Importance - The traditional Chinese medicine resource sector is a key component of the company's strategic planning [1] - The investment is intended to ensure stable supply of traditional Chinese medicine materials, strengthen market expansion, and cultivate core product brands [1] Group 3: Risk Management and Financial Impact - The company emphasized that the capital increase aligns with its strategic layout and long-term interests, with overall risks being controllable [1] - This action will not change the scope of the company's consolidated financial statements and is not expected to negatively impact its financial condition or operating results [1] - The company will enhance management of the subsidiary's operations and implement effective risk management and control measures [1]

证券代码：600129 证券简称：太极集团 公告编号：2026-002 重庆太极实业（集团）股份有限公司 关于预计公司 2026 年度日常关联交易额度 的公告 上述交易行为构成关联交易。根据《上海证券交易所上市公司自 律监管指引第 5 号——交易与关联交易》《上海证券交易所股票上市 规则》规定：上市公司与关联法人发生的交易金额在 3,000 万元以上， 且占公司最近一期经审计净资产 5%以上的关联交易，除应当披露外， 还应提交公司股东会审议，届时与该关联交易有利害关系的关联股东 将回避表决。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 本次关联交易须提交公司股东会审议。 本次日常关联交易均属本公司及下属子公司日常生产经营中 的必要的、持续性业务，对本公司及下属子公司无不利影响。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 为了优化配置资源，避免重复投资，2026 年重庆太极实业（集 团）股份有限公司（以下简称：公司）拟向关联人采购商品和接受劳 务 42,900 万元，向关联人销售商品和提供 ...

（一）增资基本情况 证券代码：600129 证券简称：太极集团 公告编号：2026-003 重庆太极实业（集团）股份有限公司 关于对全资子公司增资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●本次增资公司名称：运城市太极数智中药有限公司（以下简称 "运城数智中药"）。 ●增资金额及资金来源：重庆太极实业（集团）股份有限公司（以 下简称"公司"或"太极集团"）拟以自有资金对运城数智中药增资 4,670万元人民币。 ●本次对运城数智中药增资事宜经公司第十届董事会第三十五 次会议审议通过。根据《上海证券交易所股票上市规则》及《公司章 程》等相关规定，该事项无需提交股东会审议。 ●本次增资事宜不构成《上海证券交易所股票上市规则》和《公 司章程》规定的关联交易，也不构成《上市公司重大资产重组管理办 法》规定的重大资产重组情形。 一、本次增资概述 运城数智中药为公司全资子公司，为满足其业务发展需要，公司 拟以自有资金4,670万元对其增资，增资后运城数智中药注册资本由 30万元变更为4,700万元，仍为公司全 ...

证券代码：600129 证券简称：太极集团 公告编号：2026-001 重庆太极实业（集团）股份有限公司 第十届董事会第三十五次会议决议公告 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）第十届 董事会第三十五次会议于 2026 年 1 月 9 日以邮件方式发出书面通知， 于 2026 年 1 月 21 日以现场及视频方式召开。本次会议由董事长俞敏 先生主持，会议应到董事 13 人，实到董事 13 人，公司高级管理人员 列席了会议。本次会议的召集、召开程序符合《公司法》和《公司章 程》的有关规定，会议合法有效。会议审议并通过了如下议案： 一、关于预计公司 2026 年度日常关联交易额度的议案（具体内 容详见公司披露的《关于预计公司 2026 年度日常关联交易额度的公 告》；公告编号：2026-002） 2026 年公司拟向关联人采购商品和接受劳务 42,900 万元，向关 联人销售商品和提供劳务 80,150 万元；在关联人的财务公司日存款 余额不超过 50,000 万 ...

格隆汇1月22日丨太极集团(600129.SH)公布，运城数智中药为公司全资子公司，为满足其业务发展需 要，公司拟以自有资金4670万元对其增资，增资后运城数智中药注册资本由30万元变更为4700万元，仍 为公司全资子公司。 中药材资源板块是公司战略规划重要组成部分，公司对运城数智中药增资，主要为补充其流动资金，有 利于优化资产负债结构、提升资本实力及抗风险能力，保障中药材稳定供应，强化对外市场拓展与核心 产品品牌培育，进一步提升公司在中药材领域的整体竞争力。 ...

每经头条（nbdtoutiao）——特朗普强要格陵兰岛，丹麦一养老基金率先清仓美债，美国资产全线下 跌！欧洲手握"金融核按钮"，双方会"鱼死网破"吗？专家解读→ （记者 王晓波） 每经AI快讯，太极集团1月22日晚间发布公告称，公司第十届第三十五次董事会会议于2026年1月21日 以现场及视频方式召开。会议审议了《关于预计公司2026年度日常关联交易额度的议案》等文件。 ...

Core Viewpoint - The collaboration between Zhejiang and Fuling has evolved over 33 years, transitioning from basic support to a comprehensive partnership that enhances industrial development and improves living standards in Fuling, showcasing a successful model of east-west cooperation in China [1][6]. Group 1: Historical Context and Development - The partnership began in 1992 with the signing of the first support agreement, aimed at aiding the Three Gorges Reservoir area, marking the start of a long-term collaboration [1]. - Over the years, Fuling has transformed from an agricultural area to an industrial hub, driven by national strategies such as the Western Development and the Chengdu-Chongqing Economic Circle [1]. Group 2: Business Environment and Investment - Fuling has made significant efforts to improve its business environment, adopting a service-oriented approach to attract and retain enterprises, exemplified by the case of Huafeng Group, which established operations in Fuling after extensive engagement [2][3]. - The region has attracted over 1,000 Zhejiang merchants and more than 290 Zhejiang enterprises, with cumulative investments exceeding 50 billion yuan, contributing to about 25% of the district's industrial output [5]. Group 3: Talent and Knowledge Exchange - The collaboration has facilitated the exchange of over 390 young cadres from Fuling to Zhejiang for training, fostering a transfer of development methodologies and governance practices [4]. - Companies like Huafeng Group have brought innovative practices and cluster development strategies to Fuling, leading to the establishment of significant production bases in the region [4]. Group 4: Social and Economic Impact - Zhejiang's support has included over 5.09 billion yuan in aid for various social projects, significantly improving living conditions in Fuling [6][7]. - Initiatives such as environmental upgrades in local communities and agricultural development have resulted in increased incomes for residents, with some households seeing annual income increases of over 6,000 yuan [7]. Group 5: Future Prospects - The partnership is set to accelerate further, with 16 new investment projects from Zhejiang planned, focusing on cutting-edge sectors like new energy and electronic information, with a total investment agreement nearing 10 billion yuan [5].

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

Core Viewpoint - The company has changed its official email address for communication with investors, effective immediately from the date of the announcement [1]. Group 1: Email Change Details - The previous email address was tjzq@taiji.com, and the new email address is tjzq@sinopharm.com [1]. - Other contact information, such as office address and phone number, remains unchanged [1]. - The company requests investors to take note of the new email address and apologizes for any inconvenience caused [1].